Ketamine for depression: all studies (page 104)

The Antidepressant-like Activity and Cognitive Enhancing Effects of the Combined Administration of (R)-Ketamine and LY341495 in the CUMS Model of Depression in Mice Are Related to the Modulation of Excitatory Synaptic Transmission and LTP in the PFC

Pharmaceuticals February 1, 2023 Agnieszka Pałucha-Poniewiera, B. Bobula, Anna Rafało-Ulińska

(S)-Ketamine is the first rapid-acting antidepressant drug (RAAD) introduced for the treatment of depression. However, research is still being carried out on the search for further RAADs that will be not only effective but also safe to use. Recent data have indicated that the combined administration of (R)-ketamine and the mGlu2/3 receptor antagonist LY341495 (mixRL) induces rapid and sustained...

DOI: 10.3390/ph16020288 Full text

Ketamine, benzoate, and sarcosine for treating depression.

Neuropharmacology February 1, 2023 Yu-Jung Cheng, Chieh-Hsin Lin, Hsien-Yuan Lane

Studies have demonstrated the beneficial therapeutic effects of sarcosine, benzoate, and ketamine (including esketamine and arketamine) on depression. These drugs mainly act by modulating N-methyl-d-aspartate glutamate receptors (NMDARs) and reducing inflammation in the brain. Although ketamine, benzoate, and sarcosine act differently as the antagonists or coagonists of NMDARs, they all have...

DOI: 10.1016/j.neuropharm.2022.109351 Full text Arketamine Depression Esketamine Benzoate +1

Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.

Neuropharmacology February 1, 2023 Shigeyuki Chaki, Mai Watanabe

The efficacy of currently available medications for depression is unsatisfactory, and that has spurred the development of novel antidepressants based on a hypothesis other than the monoamine hypothesis. Recent studies have revealed the importance of the glutamatergic system as a drug target for depression, and the validity of this hypothesis has been underpinned by the discovery of the...

DOI: 10.1016/j.neuropharm.2022.109348 Full text Depression Ketamine Antidepressant Drug discovery +2

The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression

Journal of Child and Adolescent Psychopharmacology February 1, 2023 Alice Lineham, Victor J. Avila‐quintero, Michael H. Bloch et al. 20 citations

Objective: Ketamine has proven effective as a rapid-acting antidepressant agent. Several adult studies have investigated the association between ketamine's acute dissociative effects and depression response, but no studies have examined the association in adolescents with treatment-resistant depression (TRD). Methods: We conducted a secondary data analysis of 16 adolescent participants who...

DOI: 10.1089/cap.2022.0086

Inflammation, stress and depression: an exploration of ketamine’s therapeutic profile

Drug Discovery Today February 1, 2023 J. Johnston, Maximillian Greenwald, Ioline D. Henter et al. 64 citations

Well-established animal models of depression have described a proximal relationship between stress and central nervous system (CNS) inflammation – a relationship mirrored in the peripheral inflammatory biomarkers of individuals with depression. Evidence also suggests that stress-induced proinflammatory states can contribute to the neurobiology of treatment-resistant depression. Interestingly,...

DOI: 10.1016/j.drudis.2023.103518 Full text

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.

Journal of Clinical Psychiatry February 1, 2023 Balwinder Singh, Simon Kung, Vanessa K. Pazdernik et al. 64 citations

Objective: Ketamine has been redeveloped as a rapid-acting antidepressant for treatment-resistant depression (TRD). There is a paucity of literature comparing subanesthetic intravenous (IV) ketamine and US Food and Drug Administration (FDA)-approved intranasal (IN) esketamine for TRD in real-world clinical settings. We compared the efficacy and time to achieve remission/response with repeated...

DOI: 10.4088/jcp.22m14548

The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.

European Archives of Psychiatry and Clinical Neuroscience February 1, 2023 Giordano Novak Rossi, Jaime E. C. Hallak, Glen B. Baker et al. 14 citations

Although results are still preliminary, ketamine and classical hallucinogens have shown promise in recent years as novel, fast-acting antidepressants, especially for the treatment of unipolar treatment-resistant depression (TRD). Depression also seems to be related to abnormal levels of peripheral inflammatory and neurotrophic biomarkers, which may one day help to diagnose of this disorder. In...

DOI: 10.1007/s00406-022-01460-2 Full text Ketamine Treatment-resistant depression Bdnf Biomarkers +1

Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression

Human Brain Mapping January 30, 2023 Brandon Taraku, Roger P Woods, Michael Boucher et al. 23 citations

Ketamine produces fast‐acting antidepressant effects in treatment resistant depression (TRD). Though prior studies report ketamine‐related changes in brain activity in TRD, understanding of ketamine's effect on white matter (WM) microstructure remains limited. We thus sought to examine WM neuroplasticity and associated clinical improvements following serial ketamine infusion (SKI) in TRD. TRD...

DOI: 10.1002/hbm.26217 Full text

Neural Correlates of the DEEPP (Anti-suicidal Response to Ketamine in Treatment-Resistant Bipolar Depression) Study: Protocol for a Pilot, Open-Label Clinical Trial.

JMIR Research Protocols January 27, 2023 Yuliya Knyahnytska, Reza Zomorrodi, Tyler S Kaster et al.

Suicide is among the top 10 leading causes of death worldwide. Of people who died by suicide, the majority are diagnosed with depression. It is estimated that 25%-60% of people with bipolar depression (BD) will attempt suicide at least once, and 10%-15% will die by suicide. Several treatments, such as lithium, clozapine, electroconvulsive therapy, and cognitive behavioral therapy, have been...

DOI: 10.2196/41013 Full text Bipolar depression Ketamine intervention Suicidality

Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms

Pharmaceuticals January 24, 2023 Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała 10 citations

There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions in specific subpopulations. The aim of this study was to investigate the safety of intravenous ketamine treatment in relation to dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and Bipolar depression (BP) with...

DOI: 10.3390/ph16020173